Replies to post #6615 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Dear ThomasS'

With all due respect there is more than blind predjudice behind big pharma's failure to embrace NPPS. BP employs plenty of scientists. The reasons are ecconomic and are related to the regulatory process as it now exists. Things are not going to change overnight industrywide once GTCB gets an FDA approval for AT3 ( which GTCB most certainly will). Things may change for GTCB, but not industrywide. GTCB is doing the right thing by concentrating on plasma proteins and secondarily MABs. I do agree posative results DIC trials will be a tremendous boost to the stock


Please read the paper and reread my post.